Estrella Immunopharma, Inc.
Close on Oct 19, 2026
- Market cap
- $16.17M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Estrella Immunopharma has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Estrella Immunopharma filed with the SEC
PRESS RELEASE DATED JANUARY 5, 2026
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED JANUARY 6, 2026
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE ISSUED BY ESTRELLA IMMUNOPHARMA, INC., DATED DECEMBER 4, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY ESTRELLA IMMUNOPHARMA, INC., DATED NOVEMBER 3, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED AS OF JUNE 5, 2025
Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED AS OF JUNE 3, 2025
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED AS OF MAY 29, 2025
Other events · EX-99.1 to Form 8-K
Estrella Immunopharma Completes First Dose Cohort
Other events · EX-99.1 to Form 8-K
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED BY ESTRELLA IMMUNOPHARMA, INC. ON AUGUST 14, 2024.
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Estrella Immunopharma Doses First Patient in Phase I/II Trial of Anti-CD19 ARTEMIS®
Other events · EX-99.1 to Form 8-K
INVESTOR PRESENTATION DATED APRIL 10, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JANUARY 30, 2024
Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED SEPTEMBER 18, 2023
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED AUGUST 18, 2023
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED JULY 18, 2023.
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED JULY 12, 2023
Other events · EX-99.1 to Form 8-K
Extension of the Deadline for an Initial Business Combination
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Extension of the Deadline for an Initial Business
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Extension of the Deadline for an Initial Business Combination
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Extension of the Deadline for an Initial Business
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Estrella Biopharma, Inc., a biopharmaceutical
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K